Histidine and carnosine delay diabetic, deterioration in mice and protect human low density lipoprotein against oxidation and glycation

作者：Lee YT; Hsu CC; Lin MH; Liu KS; Yin MC^*

来源：European Journal of Pharmacology, 2005, 513(1-2): 145-150.

DOI：10.1016/j.ejphar.2005.02.010

• diabetes
• histidine
• carnosine
• hyperlipidemia
• cytokine

In vivo effects of histidine and camosine against diabetic deterioration in diabetic Balb/cA mice were studied. Histidine and camosine at 0.5, 1 g/l were added into drinking water. After 4 weeks intake of these agents, the content of histidine and camosine in plasma, heart and liver significantly elevated (P < 0.05). The intake of these agents significantly decreased plasma glucose and fibronectin levels (P < 0.05); however, only 1 g/l histidine and camosine treatments significantly increased insulin level (P < 0.05) in diabetic mice. Triglyceride level in heart and liver was dose-dependently reduced by histidine or camosine treatments (P < 0.05); however, only 1 g/l histidine and camosine treatments significantly reduced cholesterol level in heart and liver (P < 0.05). The administration of histidine or camosine significantly enhanced catalase activity and decreased lipid oxidation levels in kidney and liver (P < 0.05); however, only 1 g/l histidine and camosine treatments significantly increased glutathione peroxidase activity (P < 0.05). The increased interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in diabetic mice were significantly suppressed by the intake of histidine or camosine (P < 0.05). In human low density lipoprotein, histidine or camosine showed dose-dependently suppressive effect in glucose-induced oxidation and glycation (P < 0.05). These data suggest that histidine and carnosine are potential multiple-protective agents for diabetic complications prevention or therapy.

• 出版日期2005-4-18